Snibe Diagnostic Presents Immunoassay Systems and Biochemistry Analyzers
|
By LabMedica International staff writers Posted on 02 Aug 2018 |

Image: The Biolumi 8000 integrated system (Photo courtesy of Snibe).
Snibe Diagnostic (ShenZhen, China), a leading provider of chemiluminescence immunoassay solutions, presented its range of instruments at the 70th AACC (Annual Scientific Meeting & Clinical Lab Expo), which took place in Chicago, Illinois, USA, from Jul. 29 to Aug. 2, 2018.
Snibe is a professional bio-medical company that specializes in the research, production and sale of clinical laboratory instruments and in vitro diagnostic reagents. It is the first Chinese company to receive FDA clearance for a chemiluminescence immunoassay product. The range of instruments presented by Snibe at this year’s AACC included the Biolumi 8000 integrated system, MAGLUMI 800 and MAGLUMI 2000 chemiluminiscence immunoassay systems and the Biossays 240 biochemistry analyzer.
The Biolumi 8000 integrated system combines an electrolyte module, chemistry module and immunoassay module in a single platform. Tests run on the system provide physicians with a wide range of assays, including 121 immunoassay, 47 chemistry, and four electrolyte assays. The Maglumi 800 chemiluminiscence immunoassay system features three modes of operation, sample loading for up to 40 sample tubes, continuous loading, STAT available, and LIS connection. The system offers a wide test menu, with a throughput of up to 180 tests per hour and the first results available in only 17 minutes. The MAGLUMI 2000 chemiluminiscence immunoassay system has a throughput of up to 180 tests/hour with time to first results of 17 minutes and is always ready-to-use. The Biossays 240 biochemistry analyzer has a throughput of constant 240 tests/hour and allows up to 90 sample positions to be loaded continuously on sample disk with barcode recognition.
Snibe is a professional bio-medical company that specializes in the research, production and sale of clinical laboratory instruments and in vitro diagnostic reagents. It is the first Chinese company to receive FDA clearance for a chemiluminescence immunoassay product. The range of instruments presented by Snibe at this year’s AACC included the Biolumi 8000 integrated system, MAGLUMI 800 and MAGLUMI 2000 chemiluminiscence immunoassay systems and the Biossays 240 biochemistry analyzer.
The Biolumi 8000 integrated system combines an electrolyte module, chemistry module and immunoassay module in a single platform. Tests run on the system provide physicians with a wide range of assays, including 121 immunoassay, 47 chemistry, and four electrolyte assays. The Maglumi 800 chemiluminiscence immunoassay system features three modes of operation, sample loading for up to 40 sample tubes, continuous loading, STAT available, and LIS connection. The system offers a wide test menu, with a throughput of up to 180 tests per hour and the first results available in only 17 minutes. The MAGLUMI 2000 chemiluminiscence immunoassay system has a throughput of up to 180 tests/hour with time to first results of 17 minutes and is always ready-to-use. The Biossays 240 biochemistry analyzer has a throughput of constant 240 tests/hour and allows up to 90 sample positions to be loaded continuously on sample disk with barcode recognition.
Latest AACC 2018 News
- Mesa Biotech Showcases PCR Testing Platform at Clinical Expo
- Mindray Medical Unveils Chemiluminescence Immunoassay System at AACC 2018
- Abbott Diagnostics Displays Alinity Family of Systems
- Roche Diagnostics Highlights Latest Clinical Lab Solutions at AACC
- Sysmex Highlights Innovations in Flow Cytometry, Urinalysis and Hematology
- Ortho Clinical Diagnostics Unveils Next-Gen Analyzer at Lab Show
- Thermo Fisher Scientific Showcases Product Portfolio at Lab Trade Show
- EKF Diagnostics Highlights Assay Kit and POC Analyzer at AACC 2018
- Randox Laboratories Showcases Advances in Biotechnology at Clinical Lab Expo
- Beckman Coulter Life Sciences Highlights Clinical Flow Cytometry Portfolio
- Beckman Coulter Features New Hematology Analyzers and Lab Automation
- Carolina Liquid Chemistries Promotes Family of Clinical Chemistry Analyzers
- Orion Diagnostica Showcases Rapid Test and Molecular Platform at Lab Show
- Saladax Biomedical Launches Game-Changing Assays at AACC 2018
- SeraCare Life Sciences Promotes New AccuSpan Panel at Lab Expo
- Sekisui Diagnostics Showcases Clinical Chemistry and Immunoassay Analyzers
Channels
Clinical Chemistry
view channel
Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules
Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more
Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment
Patients with early-stage Alzheimer’s disease may receive anti-amyloid therapy to clear amyloid protein deposits from the brain. These treatments can slow disease progression, but they do not cure the... Read more
Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain
Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more
First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage
Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read moreMolecular Diagnostics
view channel
Rapid Genetic Test Aims to Shorten Brain Tumor Diagnosis Time
Brain tumors can be highly aggressive and difficult to treat, and The Brain Tumour Charity describes them as the biggest cancer killer of children and adults under 40. With more than 100 recognized tumor... Read more
New Oncology Assays Deliver Precise Molecular Counts with MRD-Grade Sensitivity
Precise molecular monitoring is central to managing hematologic malignancies, but traditional PCR workflows can limit sensitivity, multiplexing, and result clarity. Limited sample volumes and fragmented... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read moreImmunology
view channelBlood Test Differentiates Bacterial and Viral Infections in Febrile Infants
Fever in infants younger than 3 months is treated as a medical emergency because infections can become life-threatening while the immune system is still developing. Emergency department teams must quickly distinguish serious bacterial infections that require antibiotics from viral illnesses that usually need monitoring... Read more
New Autoantibody Test Targets Pre-Symptomatic Type 1 Diabetes Screening
Type 1 diabetes is often first recognized only after substantial beta-cell destruction, sometimes presenting as diabetic ketoacidosis. Population-scale screening could identify children at elevated risk... Read moreMicrobiology
view channel
One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more
FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more
New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read morePathology
view channel
New AI Model Maps Where Glioblastoma Could Return After Surgery
Glioblastoma is the most common malignant brain tumor in adults and the most lethal, with median survival of about 17 months after diagnosis. Even after surgeons remove all visible tumor and patients receive... Read more
Multimodal AI Supports Prostate Cancer Risk Assessment Across Diverse Cohorts
Artera’s (Los Altos, CA, USA) multimodal artificial intelligence (MMAI) platform is being featured in five abstracts at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting.... Read moreTechnology
view channel
New Automation Workflow Streamlines NGS Library Preparation for High-Volume Labs
Demand for next-generation sequencing (NGS) continues to rise as laboratories process growing sample volumes, yet library preparation remains labor-intensive and a frequent source of variability.... Read more
ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read moreIndustry
view channel
Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
Mayo Clinic Laboratories and Pathology Asia Holdings (PAH), together with subsidiary LifeStrands Genomics, announced a strategic investment and collaboration focused on expanding access to advanced diagnostics... Read more








